We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SDZ:SIXSandoz Group Ltd Analysis

Data as of 2026-09-03 - not real-time

CHF 68.86

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Sandoz Group AG trades at CHF 68.86, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Over a rolling month the price has gained 3.5%. RSI sits at 44.8, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at CHF 66.36 and resistance at CHF 75.90.
On valuation the read is overvalued — earnings multiple of 57.9 versus a 30.8 sector average, above the peer group. Analyst price targets sit 6.0% above the current price. Revenue is growing at 9.9% on a 5.5% profit margin. The 1.16% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 36.7%, a beta of 0.07 and a maximum drawdown of 17.6%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.

Top Market Events

Sandoz Group SWX:SDZ has agreed US settlements that resolve long running investigations into generic drug pricing.Strong biosimilar performance and strategic launches offset pricing pressures, boosting core EPS by 17%.Sandoz Group AG / Key word s : Half Year Results Sandoz delivers strong H1 2026 results, with outstanding biosimilar...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 64.21
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 57.9 versus sector average of 30.8
  • Trading above the 200-day average of 64.21

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 57.9 versus sector average of 30.8
  • Analyst targets imply +6.0% versus the current price
  • Dividend yield of 1.16%

Key Metrics & Analysis

Financial Health

Revenue Growth9.90%
Profit Margin5.53%
P/E Ratio57.9
ROE7.25%
ROA3.07%
Debt/Equity68.92
P/B Ratio4.1
Op. Cash FlowCHF1.9B
Free Cash FlowCHF1.4B
Industry P/E30.8

Technical Analysis

TrendBullish
RSI44.8
SupportCHF 66.36
ResistanceCHF 75.90
MA 20CHF 71.87
MA 50CHF 69.41
MA 200CHF 64.21
MACDBearish
VolumeDecreasing
Fear & Greed Index94.29

Valuation

Fair ValueCHF 51.66
Target PriceCHF 73.01
Upside/Downside6.02%
GradeOvervalued
TypeGrowth
Dividend Yield1.16%

Risk Assessment

Beta0.07
Volatility36.72%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.